GERD
Pipeline by Development Stage
Drug Modality Breakdown
On Market (1)
Approved therapies currently available
Competitive Landscape
13 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 39 trials with date data
Clinical Trials (39)
Total enrollment: 18,737 patients across 39 trials
Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS
Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity
Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases
Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients
Nexium RESPONSE Trial
Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD
An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)
An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously
Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients
Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
Sopran - Omeprazole Treatment Versus Surgery
Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects
A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects
A Study to Investigate the Effect of Food on the PK, PD of CKD-381 in Healthy Volunteers
A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects
Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1)
A Study to Compare PK, PD and Safety of CKD-381 and D026 in Healthy Subjects
A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects
PK/PD Clinical Trial of YYD601 in Healthy Adult Male
A Study to Compare PK, PD and Safety of CKD-381 in Healthy Subjects
A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease
A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive
Omega Cuff for GERD Feasibility Study
Can EndoFLIP Improve Quality of Life Before and After Fundoplication?
An Epidemiological Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease
Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD
Gastroesophageal Reflux Disease (GERD)/Nighttime Heartburn and Driving Performance
Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient Segments
Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERD
LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)
Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of GERD
Impact of GERD on Daily Life (NIS)
The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux Patients
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.